Application of Topical/Subconjunctival Bevacizumab and Topical Fluorometholone Acetate in Alkali Burn-induced Model of Corneal Angiogenesis

Dursun, Ayhan; Arıcı, Mustafa Kemal; Özeç, Ayşe Vural; Dursun, Feyza; Toker, Mustafa; Topalkara, Ayşen

doi:10.4274/tjo.40.31

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dursun et al have shown that subconjunctival bevacizumab and ranibizumab treatments may be beneficial in reducing corneal NV. 33 Additionally, they claimed that bevacizumab had a greater inhibitory impact on corneal NV than ranibizumab. They demonstrated that the longest neovascular sprout length was substantially shorter in the bevacizumab and ranibizumab groups than in the control group.…”

Section: Discussionmentioning

confidence: 99%

The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization

et al. 2022

View full text Add to dashboard Cite

Purpose To investigate the effects of subconjunctival bevacizumab, ranibizumab, and aflibercept in an experimental corneal neovascularization model. Materials and methods The eyes of 24 rats were chemically cauterized and randomly divided into four groups: bevacizumab group (0.05 mL/1.25 mg bevacizumab), ranibizumab group (0.05 mL/0.5 mg ranibizumab), aflibercept group (0.05 mL/1.25 mg aflibercept), and control group (0.05 mL saline solution). Plasma vascular endothelial growth factor (VEGF) levels were among the major measurement outcomes to assess corneal neovascularization. The collected plasmas were analyzed using the SIGMA RAB0511 Rat VEGF Elisa kit. The PCR technique and VEGF amplification procedures were used for molecular analysis. Each cornea was removed and histologically examined on day 21. Corneal images were evaluated by image analyzer software. Results In the post-injection period, the number of major corneal arteries decreased significantly in the injection groups when compared to the control group ( p = 0.037), but no statistically significant differences were noted among the injection groups ( p > 0.05). The aflibercept group had the lowest area of neovascularization. Immunohistochemical staining revealed substantially lower VEGF percentages in neovascularized arteries of the injection groups than the control group ( p = 0.015). In TUNEL staining, the mean TUNEL value (number/1hpf) was substantially greater in the control group than in the injection groups, but the mean TUNEL values were similar between the injection groups ( p = 0.019, p > 0.05, respectively). No statistically significant differences were observed between the groups in terms of corneal surface area with increased cellularity, edema, and inflammation ( p = 0.263). The mean plasma VEGF concentration in the control group was statistically greater than those in the injection groups ( p = 0.001). Conclusion Subconjunctival bevacizumab, ranibizumab, and aflibercept crossed the blood and seemed to be effective in inhibiting corneal neovascularization without causing epitheliopathy in an experimental rat model compared to the controls. However, no significant results were noted between these three anti-VEGF molecules.

show abstract

Section: Discussionmentioning

confidence: 99%

The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization

et al. 2022

View full text Add to dashboard Cite

show abstract

“…В недавнем исследовании, проведенным A. Dursun и соавт. [46], площадь неоваскуляризации роговицы, вызванной щелочным ожогом, снижалась по сравнению с контрольной группой на 28% у пациентов, получавших субконъюнктивально бевацизумаб (2,5 мг), и на 21% у пациентов, получавших субконъюнктивально ранибизумаб (1 мг).…”

unclassified

Corneal neovascularization: a modern view of molecular mechanisms and methods of therapy

Arzhimatova

Salikhov

Shemyakin

2023

Rossijskij oftalʹmologičeskij žurnal

View full text Add to dashboard Cite

This review provides a detailed summary of the issues of etiology, pathogenesis and molecular mechanisms of corneal neovascularization. Signaling molecules involved in the process of neovasculogenesis, as well as their antagonists, antiangiogenic factors, are described. The role of signaling proteins VEGF, MMP and their receptors as modern targets of therapy is described on the basis of a series of clinical studies. The potentials of gene and bioengineering therapy as a promising method of treating corneal neovascularization are presented.

show abstract

Application of Topical/Subconjunctival Bevacizumab and Topical Fluorometholone Acetate in Alkali Burn-induced Model of Corneal Angiogenesis

Cited by 2 publications

References 16 publications

The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization

The effects of subconjunctival bevacizumab, ranibizumab, and aflibercept on corneal neovascularization

Corneal neovascularization: a modern view of molecular mechanisms and methods of therapy

Contact Info

Product

Resources

About